Communiqués Catalyst Biosciences

Actions

CBIO

US14888D2080

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/07/2026			Varia. 5j.	Varia. 1 janv.
6,340 ^USD	-2,76%		-11,17%	-17,33%

16/06/25	Crescent Biopharma finalise sa fusion avec GlycoMimetics	MT
30/10/23	Beijing Continent Pharmaceutical Co. a finalisé l'acquisition de Catalyst Biosciences, Inc. (NasdaqCM:CBIO) dans le cadre d'une opération de fusion inversée.	CI

Communiqués

11/05/24	Catalyst Biosciences : Investor presentation 556.6 KB	PU
09/05/24	Catalyst Biosciences : Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Form 8-K	PU
08/05/24	Catalyst Biosciences : Notification of Conclusion of License Agreement by Gyre Pharmaceuticals Co - Form 8-K	PU
03/05/24	Catalyst Biosciences : Investor presentation 556.8 KB	PU
02/05/24	Catalyst Biosciences : Investor presentation 556.2 KB	PU
06/12/23	Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K	PU
06/11/23	Catalyst Biosciences : GNI Group Updates Full Year 2023 Consolidated Earnings Forecast - Form 8-K	PU
02/11/23	Catalyst Biosciences : Change in Certifying Accountants - Form 8-K	PU
30/10/23	Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split	AQ
22/07/23	CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO	BU
05/05/23	CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
07/04/23	CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
30/03/23	CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
30/03/23	CATALYST BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
21/03/23	Catalyst Biosciences : Investor presentation 1.6 MB	PU
21/03/23	CATALYST BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
10/03/23	CATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO	PR
02/03/23	CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
28/02/23	Catalyst Biosciences Provides Corporate Update	AQ
19/01/23	CATALYST BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
31/12/22	CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO	BU
27/12/22	CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
27/12/22	Catalyst Biosciences Completes First Steps in Reverse Merger Plan	AQ
14/11/22	CATALYST BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
04/11/22	CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ